Citi analyst Yigal Nochomovitz lowered the firm’s price target on Apellis Pharmaceuticals to $67 from $70 and keeps a Buy rating on the shares. The analyst reduced the probability of sucess for Syfovre in Europe from 75% to 50% on the news that the Committee for Medicinal Products for Human Use does not appear convinced the effects on geographic atrophy lesion growth are translating to a meaningful functional benefit, resulting in a negative trend vote.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis price target lowered by $3 at Stifel, here’s why
- Apellis downgraded at Wells with pegcetacoplan EU approval ‘unlikely’
- Wells Fargo gets more bearish on Apellis, downgrades shares
- H.C. Wainwright remain buyers of Apellis despite clouded EU approval visibility
- Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union